View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
May 20, 2022

Covid-19 vaccine and therapeutics development is unusually rapid

Covid-19 vaccines and therapeutics have been developed at a much more rapid speed than those developed for other viral infections.

By GlobalData Healthcare

The Covid-19 pandemic has continued for over two years now. Currently, the US only has 67% of its population fully vaccinated, compared with countries like China and Vietnam, where well over 80% of the population is fully vaccinated. Some hesitancy may be in part due to the perception of the speedy development of vaccines.

Covid-19 vaccines and therapeutics were developed at a rapid speed in response to the pandemic, all taking far less time than vaccines and therapeutics on average that were developed for other viral infections. As seen in Figures 1 and 2, the average duration of completed trials for viral infections was much longer than that for Covid-19.

Trials testing vaccines for viral infections other than Covid-19 took about three times longer than those for Covid-19, while trials testing therapeutics for viral infections other than Covid-19 took about five times longer than those for Covid-19. The biggest difference was seen in Phase IV trials; this is unusual, as Phase IV trials typically enrol a much larger subject pool to test long-term safety and effectiveness.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena